Based on the additive interaction between neratinib and trastuzumab observed in the SKBR3 and BT474 cell lines, we extended the analysis of the combination treatment to 7 additional HER2 amplified breast cancer cell lines, including cell line models of innate trastuzumab resistance. The gene discussed is ERBB2; the disease is breast carcinoma.